Feedback
Settings

Settings

Goto Application

3,291 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(YXNIEZJFCGTDKV-JANFQQFMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 330
1.20260144861COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION
US - 28.05.2026
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 19121711 Applicant BioNTech SE Inventor Ugur Sahin

This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

2.20260146262METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS
US - 28.05.2026
Int.Class C12N 15/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
88using microencapsulation, e.g. using liposome vesicle
 Appl.No 19123603 Applicant ModernaTX, Inc. Inventor Michael H. SMITH

In some aspects, a method can include feeding an eLNP solution to a first inlet, the first inlet splitting into a first sub-inlet and a second sub-inlet, the first sub-inlet connected to a first side of a central region of a mixer, the second sub-inlet connected to a second side of the central region of the mixer, feeding an mRNA solution to a second inlet, the second inlet connected to a third side of the central region of the mixer, the third side orthogonal to the first side and the second side, mixing the eLNP and the mRNA in the central region to form encapsulated eLNP, and transferring the encapsulated eLNP out of the central region via an outlet, the outlet coupled to a fourth side of the central region, the fourth side opposite the third side.

3.2026516460療法用の抗原特異的生理的樹状細胞
JP - 25.05.2026
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
 Appl.No 2025564098 Applicant エール・ユニバーシティ Inventor ソボレフ，オルガ
本発明は、生理的樹状細胞および少なくとも１種のｍＲＮＡを含む組成物に関する。本発明は、治療的処置における使用のための、生理的樹状細胞および少なくとも１種のｍＲＮＡを含む組成物にさらに関する。
4.20260137630COMPOSITIONS AND METHODS FOR T CELL TARGETED DELIVERY OF THERAPEUTIC AGENTS AND ACTIVATION OF T CELLS
US - 21.05.2026
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
 Appl.No 19119028 Applicant The Trustees of the University of Pennsylvania Inventor Michael J. Mitchell

The present disclosure relates, in part, to immune cell targeted lipid nanoparticle (LNP) compositions, and methods of use thereof for ex vivo delivery of nucleic acid molecules and/or therapeutic agents to a target cell. In certain embodiments, the LNPs described herein are suitable for T cell activation. In certain embodiments, the nucleic acid molecules encode chimeric antigen receptors (CARs). In certain embodiments, the present disclosure relates to the use of the LNPs described herein for the treatment, prevention, and/or amelioration of diseases and/or disorders, including but not limited to cancer.

5.20260138999REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS
US - 21.05.2026
Int.Class C07F 9/6578
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
9Compounds containing elements of Groups 5 or 15 of the Periodic Table
02Phosphorus compounds
547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
6564having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
6578having phosphorus and sulfur atoms with or without oxygen atoms, as ring hetero atoms
 Appl.No 19376589 Applicant Bristol-Myers Squibb Company Inventor Dongmin XU

The disclosure describes chiral P(V)-based reagents and their uses for the modular, scalable, and stereospecific synthesis of chiral phosphines, phosphine oxides and particular oligonucleotides.

6.2026083002改変された遺伝暗号表を有する翻訳系
JP - 19.05.2026
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No 2026020069 Applicant 中外製薬株式会社 Inventor 西村　香緒梨
【課題】コドンの読み分けを可能にする新たな手段を提供する。
【解決手段】特定のコドンボックスにおいて、pCpA-アミノ酸と3’末端のCA欠損tRNAをligaseで結合させて調製したアミノアシル化tRNAを使用することで、wobble塩基対の存在により困難であったNNAとNNGコドンを読み分けることに成功した。さらに、同じコドンボックスのNNUもしくはNNCコドンに別のアミノ酸を割り当て、NNU、NNAおよびNNGまたはNNC、NNAおよびNNGの３つのコドンを含む配列を翻訳してコドンの読み分け能を評価したところ、目的のコドンからそれに対応するアミノ酸のみが特異的に翻訳され、正確な読み分けに成功した。またｔＲＮＡボディーの配列を変更しても同様の効果が得られることが確認された。
【選択図】なし
7.122070137方法
CN - 19.05.2026
Int.Class A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
 Appl.No 202480067715.0 Applicant 百欧恩泰欧洲股份公司 Inventor J·施莱雷斯
本发明提供一种利用逆转录和PCR（优选液滴数字PCR）测定RNA样本的至少一个质量参数的方法。该质量参数可以是：(a) 含有n种RNA分子种类的RNA分子的RNA样本中的两种或更多种RNA分子种类的定量比；(b) 所述RNA样本中n种RNA分子种类的身份，其中n为至少为2的整数；(c) 含有n种RNA分子种类的RNA分子的RNA样本的完整性，其中n为至少为1的整数；或(d) 包含感兴趣RNA分子的配制RNA样本的效力。
8.122070365包含高活性反式扩增复制酶的系统和组合物
CN - 19.05.2026
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No 202480066788.8 Applicant 百欧恩泰欧洲股份公司 Inventor M·佩尔科维奇
本文描述了使用与相应的未经修饰的聚合酶相比具有增加的反式扩增活性的经修饰的RNA依赖性RNA聚合酶的可复制RNA系统及其在治疗和预防疾病的方法中的用途。
9.2026515981ワクチン接種用の抗原特異的生理的樹状細胞
JP - 19.05.2026
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 2025564031 Applicant エール・ユニバーシティ Inventor ソボレフ，オルガ
本発明は、生理的樹状細胞および少なくとも１種のｍＲＮＡを含む組成物に関する。本発明は、ワクチン接種における使用のための、生理的樹状細胞および少なくとも１種のｍＲＮＡを含む組成物にさらに関する。
10.2026516002志賀毒素検出用の酵素基質
JP - 19.05.2026
Int.Class C12Q 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
34involving hydrolase
 Appl.No 2025564155 Applicant ロベルト－コッホ－インスティトゥート Inventor フライガー，アントイェ
本発明は、a）真核生物／哺乳動物の60Sリボソームサブユニットのサルシン－リシンループ（SRL）のヌクレオチド配列であって、SRLヌクレオチド配列が少なくとも1つのアデニンを含む、ヌクレオチド配列と、b）少なくとも1つの切断依存性標識とを含むオリゴヌクレオチドに関し、オリゴヌクレオチドは一本鎖である。好ましくは、オリゴヌクレオチドは、少なくとも1つのループ構造又はステム－ループ構造を構成する。更なる態様において、本発明は、試料中の活性な志賀毒素を検出する方法に関し、a）本発明による少なくとも1つのオリゴヌクレオチドを準備する工程と、b）志賀毒素について試験される試料を提供する工程と、c）試料を少なくとも1つの一本鎖オリゴヌクレオチドと共にインキュベートする工程と、d）標識からのシグナルを検出する工程であって、シグナルが試料中の志賀毒素の存在を示す、工程とを含む。本発明はまた、本発明による少なくとも1つのオリゴヌクレオチドを含むキットを含む。
【選択図】なし

# -